Amgen Aktie News

Study Also Shows 36% Reduction in Risk of Heart Attack  Repatha is the First and Only PCSK9 Inhibitor to Significantly Reduce the Risk of First Heart Attack and Stroke THOUSAND OAKS, Calif. , Nov. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha® (evolocumab) achieved statistically significant and...

Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events by 25% for at-risk patients who have never had a heart attack or stroke, according to results from a large study presented on Saturday.

Amgen is a biotech leader with strong sales growth, key products outperforming, and an impressive R&D pipeline fueling future prospects. Despite political headwinds and margin pressures, AMGN raised full-year guidance and is implying resilient bottom-line growth. The stock trades at a significant valuation discount to sector peers, making AMGN an attractive value play in the current environment.

Amgen Inc. NASDAQ: AMGN just delivered a strong beat-and-raise quarter. That's pushed the stock to within striking distance of its 52-week high.

The biotech and pharmaceutical mainstay posted its third-quarter results. It was a beat-and-raise quarter that featured double-digit growth on the top line.

Amgen remains a compelling long-term buy, supported by robust R&D investment and a promising drug pipeline for future growth. AMGN delivered strong Q3 results, with double-digit revenue and volume growth across key segments, and maintains an attractive 3.2% dividend yield. Valuation metrics remain favorable, and management's focus on R&D and operating margins positions AMGN to capture expanding...

Amgen Inc. ( AMGN ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Casey Capparelli Robert Bradway - Chairman, CEO & President Peter Griffith - Executive VP & CFO Murdo Gordon - Executive Vice President of Global Commercial Operations James Bradner - Executive Vice President of Research & Development Conference Call Participants Salveen Richter - Goldman Sachs Group, In...

Der US-Biotechkonzern Amgen US0311621009 blickt nach einem überraschend gut gelaufenen Quartal noch optimistischer auf 2025.